Skip to main content
. Author manuscript; available in PMC: 2020 Dec 12.
Published in final edited form as: Clin Nucl Med. 2017 Jun;42(6):436–443. doi: 10.1097/RLU.0000000000001629

Table 9.

Effectiveness of Lu-177 DOTA- Octreotate with breakdown according to “mid-gut type” and “Non mid-gut type” neuroendocrine tumors from July 2015 to July 2016

Number of cases
(%)
PD
(%)
SD
(%)
PR
(%)
CR
(%)
Not Evaluable
(%)
MID-GUT 2015 & 2016 59
(41.2%)
19
(32.2%)
32
(54.23%)
2
(3.38%)
--- 6
(10.2%)
Non
Mid-Gut
2015
84
(58.8%)
25
(29.7%)
33
(39.2%)
21
(25%)
--- 5
(5.9%)
Non
Mid-Gut 2016
84
(58.8%)
34
(40%)
33
(39.2%)
12
(14.3%)
--- 5
(5.9%)